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Abstract
Background: Parkinsonism describes Parkinson’s disease and other associated degenerative
changes in the brain resulting in movement disorders. The motor cortex, extrapyramidal tracts
and nigrostriatal tract are brain regions forming part of the motor neural system and are
primary targets for drug or chemotoxins induced Parkinsonism. The cause of Parkinsonism has
been described as wide and elusive, however, environmental toxins and drugs accounts for
large percentage of spontaneous cases in humans. A common mechanism in the cause and
progression of drug/chemotoxin induced Parkinsonism involves calcium signalling in; oxidative
stress, autophagy, cytoskeletal instability and excitotoxicity
.Aim: This study sets to investigate the effect of targeting calcium controlling receptors,
specifically activation of Vitamin D3 receptor (VDR) and inhibition of N-Methyl-D-Aspartate
Receptor (NMDAR) in the motor cortex of mice model of drug induced Parkinsonism. Also we
demonstrated how these interventions improved neural activity, cytoskeleton, glia/neuron
count and motor–cognitive functions in vivo.
Methods: Adult mice were separated into six groups of n¼ 5 animals each. Body weight
(5mg/kg) of haloperidol was administered intraperitoneally for 7 days to block dopaminergic
D2 receptors and induce degeneration in the motor cortex following which an intervention of
VDR agonist (VDRA), and (or) NMDAR inhibitor was administered for 7 days. A set of control
animals received normal saline while a separate group of control animals received the
combined intervention of VDRA and NMDAR inhibitor without prior treatment with haloperidol.
Behavioral tests for motor and cognitive functions were carried out at the end of the treatment
and intervention periods. Subsequently, neural activity in the motor cortex was recorded in vivo
using unilateral wire electrodes. We also employed immunohistochemistry to demonstrate
neuron, glia, neurofilament and proliferation in the motor cortex after haloperidol treatment
and the intervention.
Result/Discussion: We observed a decline in motor function and memory index in the
haloperidol treatment group when compared with the control. Similarly, there was a decline in
neural activity in the motor cortex (a reduced depolarization peak frequency). General cell loss
(neuron and glia) and depletion of neurofilament were characteristic anatomical changes seen
in the motor cortex of this group. However, Vitamin D3 intervention facilitated an improvement
in motor–cognitive function, neural activity, glia/neuron survival and neurofilament expression.
NMDAR inhibition and the combined intervention improved motor–cognitive functions but not
as significant as values observed in VDRA intervention. Interestingly, animals treated with the
combined intervention without prior haloperidol treatment showed a decline in motor function
and neural activity.
Conclusion: Our findings suggest that calcium mediated toxicity is primary to the cause and
progression of Parkinsonism and targeting receptors that primarily modulates calcium reduces
the morphological and behavioral deficits in drug induced Parkinsonism. VDR activation was
more effective than NMDAR inhibition and a combined intervention. We conclude that
targeting VDR is key for controlling calcium toxicity in drug/chemotoxin induced Parkinsonism.
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Introduction
Parkinsonism describes Parkinson’s disease (PD) and (or)
other associated movement disorders that can be observed in
the behavior of an individual (Picillo et al., 2014; Zhu et al.,
2014). Several discrete parts of the mammalian brain are
known to be involved solely or in synergy with other brain
areas in the cause and progression of Parkinsonism (Ricciardi
et al., 2014). Although PD is the second leading cause of
neurological disorders, the main cause has been described as
wide and elusive. Some of the known features of
Parkinsonism includes, degeneration of motor neurons,
inflammation, depletion of dopamine in the nigrostriatal
tract, hyper phosphorylation of cytoskeletal proteins and
multifactorial genetic factors involved in spontaneous muta-
tions in more than several genes (Konieczny et al., 2014; Liu
et al., 2010; Su¨hs et al., 2014). Mutation of PD genes (Parkin
and PINK 1), environmental influence on gene expression,
mitochondria defects, drug and chemotoxins are some of the
common cause of Parkinsonism already identified (Alcalay
et al., 2014; Barbiero et al., 2014; Bjo¨rkblom et al., 2013; Liu
et al., 2013; Osuntokun, 1981; Puri, 2014).
Anatomical changes in many areas of the brain have been
described in Parkinsonism (Busceti et al., 2013); ultimately,
selective vulnerability of neurons in the motor neural circuit is
often implicated in prevalence of the disease (Biundo et al.,
2013; Bosch-Bouju et al., 2013). It is known that cortical
projections of the nigrostriatal tract synapse in the layers of the
motor cortex which sends extra cortical fibers into the other
brain areas to control motor function, thus, degeneration along
this tract will impair motor coordination (Braak & Braak,
2000; Braak et al., 2000; Ho¨glinger et al., 2003). The most
significant change is often associated with loss of pyramidal
cells in the motor area, extrapyramidal tracts and dopamin-
ergic neurons of the nigrostriatal tract (Chou et al., 2014;
Dehay et al., 2012; Engel et al., 2008; Patil et al., 2014).
Factors that induces stress, inflammation or selectively targets
these neurons are implicated as causative agents in
Parkinsonism (Alcalay et al., 2014; Barbiero et al., 2014).
For example, pigmented dopaminergic neurons of the
nigrostriatal tracts are known to be selectively destroyed
through direct administration of 6-OHDA into the medial fore
brain bundle (mfb) or striatum leading to dopamine depletion
(Walker et al., 2010). Also, prolonged pharmacological
inhibition of dopaminergic D1/D2 receptors induces synaptic
denervation in the nigrostriatal system (Faucheux et al., 2003;
Plum et al., 2013), and inhibit striatal transmission to the
motor cortex (Ferrer et al., 2012; Hou et al., 2010). In addition,
heavy metals and chemotoxins generate reactive oxygen
species (ROS) which induces calcium surge, membrane
damage, cytoskeletal instability and cell death (Sugiyama &
Sun, 2014). Despite the involvement of calcium toxicity in
autophagy and cytoskeletal instability in cortical and striatal
degeneration, dopamine replacement (L-DOPA) remains the
most used treatment for PD. However, in therapeutic devel-
opment, receptors involved in the control of calcium might be
potential targets for relieving the synaptic denervation and
associated degenerative changes in the brain.
Vitamin D3 receptor (VDRA) is a steroid receptor widely
distributed in the brain and highly concentrated in the
pigmented nigrostriatal tract and motor cortex (Cui et al.,
2013; Liu et al., 2013). It is suspected to be involved in
melanin synthesis, cytoskeletal stability and the control of
calcium in the motor area (Eyles et al., 2005). An indirect
control of calcium in NMDAR inhibition has been described
in reversal of excitotoxicity in in vitro and in vivo (Chen et al.,
2013; Iba´n˜ez-Sandoval et al., 2007). Furthermore, potenti-
ation of the NMDAR is involved in glutamate excitotoxicity,
degeneration in the nigrostriatal tract and motor cortex
through the increase of inward calcium current that elevates
cerebral calcium and induces excitotoxicity (Chen et al.,
2013).
Interestingly, our previous findings show that activation of
VDR by VDR agonists (VDRA) and inhibition of NMDAR
in vitro reduces calcium toxicity and stabilizes microtubules,
thus, preventing excitotoxicity and synaptic denervation
(Blandini et al., 1996; Hurley & Dexter, 2012; Ogundele
et al., 2014; Villalba & Smith, 2010). Despite the potential as
therapeutic targets, VDR and NMDAR mediated calcium
reduction in reversal of cortical degeneration (Parkinsonism)
is still relatively unexplored. Using anatomical and electro-
physiological approaches, we have elucidated the effect of
VDR potentiation/NMDAR inhibition in improving cortical
degenerative changes and neural activity of the motor cortex
in drug-induced Parkinsonism. Furthermore we sought to
identify, comparatively the effect of VDR potentiation and
(or) NMDAR inhibition on neural depolarization potential
and motor–cognitive functions in vivo.
Methods
Animals preparation: Male adult BLAB/c mice weighing
between 20 and 25 g were procured from the animal holding
facility of Afe Babalola University. Animals (n¼ 30) were
separated into three primary groups A, B and C. Group A
(n¼ 5) received normal saline for 2 weeks; representing the
negative control. Group B (n¼ 15) was treated with
intraperitoneally administered aaloperidol (5 mg/kg BW) for
7 days, following which they were separated into three (3)
sub-groups B1, B2 and B3 (n¼ 5 animals each). B1 received
Vitamin D3 (VD3) (Oral; 70 mg/kg), B2 was treated with
6 mg/kg BW of ketamine (intraperitoneal) while B3 was
treated with both VD3 and ketamine for 7 days post-treatment
with haloperidol. Group C received normal saline for 7 days
following which they were treated with haloperidol (C1) and
VD3 + ketamine for 7 days (C2) (n¼ 5 each) (Table S2). All
protocols were approved by the Animal Use Ethics
Committee of the Afe Babalola University.
Behavioral studies: The animals were trained for 4 days in
the behavioral testing area to allow them acclimatize to the
room and the equipments to be used for each test to be
conducted. Where necessary, scientists helped animals to
move, navigate or climb to aid learning and preparation of the
animals for the actual test.
Rotarod test: This was done to evaluate motor performance
in the animals following treatment with haloperidol, ketamine
(NMDAR) and (or) vitamin D3 (+VDR). Each test consists
of three time trials on the rotarod (T1, T2 and T3). It involves
gradually increasing the speed from 3 rpms to reach a
maximum speed of 35 rpm in 3 min for each trial (n¼ 5
2 O. M. Ogundele et al. Drug Chem Toxicol, Early Online: 1–13
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animals in each group for each trial). An inter trial time (IT)
of 20 min was observed for the three consecutive trials. A total
of 15 trials was conducted for each group and was recorded
using a high definition video recorder. Subsequently, we used
inter reader variability to determine the maximum duration
spent by an animal on the rotarod (latency of fall), also the
number of passive rotations made in each trial.
Open Field Test (OFT): This was used to measure the
exploration activity of the animals. A wooden cage open field
area was marked to contain 15 15 squares of 18 cm 18 cm
each. The distance travelled and the number of lines crossed
were recorded using a high definition video recorder kept at a
safe distance to cover the entire open field area (OFA). The
frequency of line crossed was determined by using independ-
ent investigators to score the line crossing by each animal
(n¼ 5 per group).
Elevated Plus Maze (EPM): Using a modified design,
anxiety linked behaviors were accessed in the animals (n¼ 5
per group). These include the frequency of head dipping
(HD), open arm duration (OAD), closed arm duration (CAD),
closed arm entries (CAE) and open arm entries (OAE). The
duration of the test was 3 min per mice.
Novel Object Recognition (NOR): Object recognition
memory function was evaluated using the NOR test. A
75 cm 50 cm 30 cm transparent box was used. Three days
prior to the habituation sessions, the mice were exposed to the
box to familiarize with the environment. For the actual test, the
animals were exposed to two identical objects for five minutes
(Trial 1; T1). An inter trial time of 30 min was observed after
which the animals were returned to the testing area for the
second trial (T2). Time allowed for T2 was 5 min during which
one of the old objects was replaced with a novel object.
Exploration was scored when the nose of the animal is less than
2 cm from the object, while sitting on the object was excluded.
Using inter reader variability, the videos were analyzed to
estimate the time spent on rearing old object and new object in
T2 to calculate the memory index [time spent on new object/
total time spent on rearing both objects 100] (Li et al., 2011).
Electrophysiology: Animals were anaesthetized using an
isofluorane chamber. A dental drill was used to make holes on
specific stereotaxic coordinates to pin point the motor cortex.
The wired electrodes in carbon tubes were passed into the
memory cortex approximately 4.68 mm anterior to the bregma
and 2.5 mm deep (Figure 1h). Subsequently, the electrodes
were fixed to the cranium using a rubber platform and
orthopaedic glue. The dissected region of the scalp was
cleaned using an antiseptic agent and animals were allowed to
stay for 48 h to recover and move freely in the cage. In order to
record the depolarization potential in vivo, the animals were
transferred to modified cages and the electrodes were
connected to a spiker box (Backyard Brains, Ann Arbor,
MI). Neural activity was captured using the Audacity Software
(version 2.0.5) on PC and analyzed in SigView (Version 2.6.1
by Signal Labs) to determine the maximum peak frequency
and time epoch depolarization potential (Figure 1g and h).
Immunohistochemistry
The animals were anaesthetized using iofluorane and
decapitated. The whole brain was excised and perfused in
cold artificial cerebrospinal fluid [ACSF: 125 mM NaCl,
25 mM NaHCO3, 3 mM KCl, 1.25 mM NaH2PO4, 1 mM
MgCl2, 2 mM CaCl2 and 25 mM glucose maintained at 4
C]
and transferred to formolcalcium for 14 h. The brains were
processed routinely to obtain paraffin wax embedded tissue
block. Thick sagittal sections (7 mm) were cut using a
microtome (Leica, Wetzlar, Germany). Sections were recov-
ered and placed in urea and microwaved for antigen retrieval
immunohistochemistry. Immunostaining with antibodies for
antimice GFAP, NSE, NF and Ki-67 (Novocastra; Leica
Biosystems, Wetzlar, Germany) were used to examine the
protein expression in the motor cortex. A dilution of 1:200 (in
PBS) was used for all primary antibodies. The color reaction
was developed using avidin-biotin-peroxidase immunohisto-
chemistry (Novocastra; Leica Biosystems, Wetzlar, Germany)
and DAB (Sigma) as the polymer.
Cell count and statistical analysis: The images were
acquired using an Optronics Digital Camera connected to a
computer interface (MagnaFire) and an Olympus BX-51
Binocular research microscope (Olympus America, Newark,
NJ). The cells were counted using Image J (NIH, Bethesda,
MD) at a magnification of 100. For each image, the
background was subtracted to remove noise following which
the color threshold was set to generate black and white outline
of cells in the section. Individual cells were denoted in binary
mode of Image J (using the fill hole) followed by insertion of
1 pixel lines between cells (water shed; Image J). In subsequent
processing, particle size was set at 128 pixels to eliminate
smaller sized points and immunonegative cells in the sections.
The count of immunopositive cells (GFAP, NSE, Ki-67 and
NF) were determined at different microscopic fields (n¼ 7) for
n¼ 5 sections in all groups. Data obtained was analyzed using
ANOVA and Bon Ferroni Post Hoc test with significance set at
p50.05 [GraphPad Prism (Version 6.0)]. A p value of less than
0.05 was considered statistically significant, thus, p50.05 (*),
p50.01 (**) and p50.001 (***).
Note: All behavioral test and cell count data were plotted
as bar charts (mean) and error bars represents standard error
of mean (SEM). Neural activity recording was presented as
bar chart (mean of maximum frequencies) and standard
deviation (error bar).
Results
Brain wave activities of the motor area
Comparing the peak activity and the root mean square (RMS)
(extracellular neural recording with time epoch) for all
groups, showed that the control recorded the highest neural
activity (peak value of 32 440 Hz; Figure 1a and g) while the
haloperidol treated group (DPD) had the lowest neural
activity (429 Hz; Figure 1b and g). We probed further by
comparing peak frequency for the control and DPD with those
of animals in which PD was induced followed by an
intervention of NMDAR inhibition, VDR activation or both.
A significant increase in neural activity was observed in the
VDR activation group (DPD/+VDR; 32 364 Hz) and the
combined intervention group (DPD/+VDR/NMDAR;
32 442 Hz) when compared with the control (Figure 1d and
f). Interestingly, we observed an increased peak in after
blockade of the NMDAR (DPD/NMDAR; 25 678 Hz) when
DOI: 10.3109/01480545.2014.975355 Vitamin D improves motor fucntion in Parkinsonism 3
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Figure 1. (a–f) Unilateral electrode recording form the motor area of mice. (a) Neural depolarization potential recording in the motor cortex of the
control animals with a maximum peak 32 440 Hz and root mean square value (standard deviation) of 7.165 ±009. (b) The lowest depolarization peak
Continued
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compared to the DPD and control, however, this was less
significant when compared to the VDR activation or the
combined intervention group (Figure 1e and e).
We next considered the amplified spikes (0.01 s) showing
depolarization action potential (Figure 1g and Table S1) for
the treatment groups and control. Because regulatory role of
VDR activation and NMDAR inhibition is not well estab-
lished, we analyzed depolarization phases in the motor cortex
of the intervention groups to compare the neural activity for
VDR activation versus NMDAR inhibition. NMDAR inhib-
ition (DPD/NMDAR) caused repeated irregular depolariza-
tion spikes while the DPD/+VDR and DPD/+VDR/
NMDAR showed spike patterns similar to the control
(although a time delay of 0.02 s was observed in these groups
when compared with the control). The effect of the interven-
tion was examined in a separate set up of control animals in
which PD was not induced but animals received intervention
for 7 days. A reduction in neural activity was observed
(+VDR/NMDAR; 14 870 Hz) when compared with the
control and the PD intervention groups (Figure 1c and g).
Subsequently, we compared the neural time epoch recording
in vivo to the observed motor–cognitive function across the
groups using behavioral assays. After prolonged pharmaco-
logical inhibition of dopaminergic (D2) receptor with halo-
peridol, the animals showed delayed motor response and
staggered gait in motor function tests. Similarly, animals that
received intervention without prior induced PD showed a
reduced motor coordination (Figures 2 and, 3a and b).
Motor function
In order to determine the significance of the observations in
neural epoch recording after induced PD and intervention, the
motor function test outcomes were compared with the cortical
neural activity in vivo (Figure 1g). Motor function and
coordination were measured using batteries of tests to assess
exploratory movement (open field test) and forced motor
coordination (Rotarod). To reduce the margin of error, four
(4) blinded investigators analyzed the videos independently.
Dopaminergic (D2) inhibition with haloperidol impaired
exploratory motor function significantly when compared
with the control (p50.001) (Figure 2). Similar to our
observations in cortical neural activity recordings, interven-
tion through VDR activation (DPD/+VDR) improved the
exploratory activity (p50.05) while NMDAR inhibition
(DPD/NMDAR) caused no significant change when com-
pared to the DPD and control. In rotarod test, the latency
of fall and number of passive rotations were quantified
statistically. The DPD recorded the least latency of fall (LOF),
that is the least duration on the treadmill, while the control
had the highest latency of fall (p50.05) (Figure 3a). Motor
coordination improved significantly in the VDR-activation
intervention group when compared with the control and DPD
(p50.05). However, DPD/NMDAR and DPD/+VDR/
NMDAR showed no significant change in the LOF when
compared with the control but was significant versus the DPD
(Figure 3a). The least frequency of passive rotations was
Figure caption Continued
was observed in the DPD (429 Hz) after the administration of haloperidol. Motor–cognitive impairment was also observed in this group. (c) A separate
treatment group in which VDRA and NMDAR antagonists were administered without any prior haloperidol treatment (NS/+VDR/NMDAR) showed a
reduction in neural activity and decline in motor function. A maximum depolarization peak of 14 870 Hz was recorded in this group. This is probably
due to the effect of this treatment in reducing cerebral calcium to a level below normal in untreated animals. (d) An improved neural activity was
recorded in the VDRA intervention group after initial haloperidol treatment and impaired motor function (DPD/+VDR). A maximum peak value of
32 364 Hz was recorded for this group with a RMS value of 6.96 ± 009 similar to the value obtained in the control. (e) An irregular depolarization
potential was observed in the haloperidol treatment mice after an intervention with NMDAR antagonist in vivo. DPD/NMDAR recorded a maximum
peak of 25 678 Hz significantly lower than that of the control and VDRA intervention groups. (f) A separate group of animals treated with haloperidol
received a combined intervention of NMDAR blockade and VDRA (DPD/+VDR/NMDAR). Neural activity improved after the treatment with
maximum peak reaching 32 442 Hz, similar to the control and the DPD/+VDR. Animals in this category also showed an improved motor function in
behavioral test. (g–h) Statistical analysis of neural activity recording. (g) Unilateral electrodes were placed in the left motor cortex while the animals
engage in motor gestures in a restricted area. The maximum frequency (bar chart) denotes the peak depolarization potential recorded while the
extracellular neural activity epoch (root mean square) is expressed as the standard deviation for each group (error bar). A decline in neural activity in
time epoch recording was observed in the haloperidol treatment group and significantly increased in all the intervention groups (p50.05). Neural
activity also decreased in the intervention group without prior haloperidol treatment (NS/+VDR/NMDAR). (h) Electrode placement in the motor
cortex of adult mice. The wire electrodes were placed in the layer 2/3 which receives somatosensory thalamocortical and striatal afferents responsible
for motor coordination in the neural circuit of the motor cortex (*p50.05).
Figure 2. Frequency of lines crossed in OFT. Exploratory motor
function was measured in OFT. The control recorded the highest
frequency of lines crossed while the haloperidol treatment with no
intervention (DPD) had the least exploratory activity in this test.
Similarly, VDRA intervention (DPD/+VDR; p50.05) and a combined
treatment (DPD/+VDR/NMDAR; p50.01) caused an improvement in
exploratory motor function when compared to the haloperidol treatment
group without intervention (DPD). Pharmacological intervention through
NMDAR blockade (DPD/NMDAR) gave no significant change in
motor function when compared to the DPD and control. Also, animals
that received intervention without prior haloperidol treatment showed
an increase in exploratory activity when compared to the DPD
(*p50.05, **p50.01 and ***p50.001).
DOI: 10.3109/01480545.2014.975355 Vitamin D improves motor fucntion in Parkinsonism 5
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recorded in the VDRA intervention group when compared to
the DPD while the group that received intervention without
prior treatment (NS/+VDR/NMDAR) recorded displayed
passive rotations throughout the duration of the test
(out layer).
Non-motor function
Novel object recognition (NOR) test was administered to
measure the spatial memory function. We estimated the
average exploration time on old and new objects (Figure 4)
and subsequently determined the memory index (MI). The
control group recorded the highest exploration time on both
objects while the DPD explored the old object more than the
new (low memory index). After VDRA intervention, the
DPD/+VDR showed an improved memory index when
compared with the control (p50.05) and DPD (p50.05).
Interestingly, the +VDR/NMDAR did not explore the new
object at all thus demonstrating a reduced memory index
(Figure 4B) similar to the reduced motor function (Figures 2
and 3b) and neural activity (Figure 1g). Anxiety was
evaluated in elevated plus maze (EPM) which included the
open arm duration (OAD), closed arm duration (CAD), open
arm entries (OAE), closed arm entries (CAE) and frequency
of head dipping (HD). The DPD recorded the highest CAD
duration, thus signifying anxiety (Figure 5a). The +VDR/
NMDAR recorded the highest OAD when compared
with the other groups (Figure 5b). The number of OAE
and CAE was highest in the DPD/+VDR while HD was least
in this intervention group. This represents a reduced anxiety
and improved exploratory behavior after VDRA
intervention when compared with the control and DPD
(Figure 5c and d).
Immunohistochemistry
GFAP: Glia activation and increased cell number were
observed in the treatment groups. All treatments and control
recorded glia scores (GFAP+) that was significantly higher
than the DPD group (p50.001). Glia loss in the DPD
treatment also correlated with general cell loss in the cortex of
these animals (Figure 6a and d).
NSE: The expression level of the neuronal marker was
higher in the DPD/+VDR treatment when compared with the
control and the DPD treatment (p50.001). However, no
significant difference was observed in the expression of
NSE in the DPD, DPD/NMDAR and +VDR/NMDAR
(Figure 6b and e).
NF: The DPD showed a significant decline in NF
deposition within the motor cortex. This represents a loss of
neuronal cytoskeleton and synaptic connections in the motor
cortex. An increase in NF expression was observed in the
intervention group after VDRA treatment (DPD/+VDR) with
a significance of p50.001 when compared with the control
and DPD. NF deposition also increased in the DPD/
NMDAR and the DPD/+VDR/NMDA intervention
groups (Figure 6c and f).
Ki-67: The DPD showed a decline in cell number which
was observed both in the neuron (NSE) and glia (GFAP)
count. The Ki-67(+) cell distribution increased in the VDRA
intervention group (DPD/+VDR); this corresponded to the
increase in GFAP(+) and NSE(+) cell count in the motor
Figure 3. Rotarod test for motor function expressed as latency of fall (LOF) and number of passive rotations (PRs). (a) The LOF was determined by
estimating the duration spent by each animal on the rotarod when the speed was gradually increased from 4 to 34 rpm. The maximum time allowed was
3 min for each test. A total of n¼ 5 animals were used for the actual test of three trials T1, T2 and T3. After haloperidol treatment, DPD showed a
decline in motor function (p50.05) when compared with the control. Haloperidol treated animals that received VDRA intervention (DPD/+VDR)
recorded the longest duration on the rotarod supporting an improved motor activity initially demonstrated in OFT (Figure 2). Although the DPD/
+VDR/NMDAR showed an improved exploratory activity in OFT, a reduced motor function was recorded in rotarod test (similar to the DPD/
NMDAR) when compared with the control. However, all treatments and control gave scores higher than the DPD (significant at p50.05*). (b) The
number of passive rotations (PRs) was recorded per animal for the three trials. The highest number of PRs was observed in the DPD/+VDR/NMDAR
which recorded a low LOF for the same test duration. The +VDR/NMDAR recorded no PR while the DPD and DPD/NMDAR recorded
value close to the control. It is important to note that the DPD/+VDR recorded the highest latency of fall in (A) and the least frequency of passive
rotations (*p50.05).
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cortex of this group. Ultimately, this indicates the role of
VDRA treatment in improving cortical neuronal survival.
Increased count and proliferation were also observed in the
DPD/+VDR/NMDAR (p50.01) and DPD/NMDAR
(p50.05), although not as significant as that in the DPD/
+VDR (p50.001) (Figure 7a and b).
Discussion
Taken together, the findings of this study suggest that
NMDAR and VDR receptor targeted mechanisms are
involved in the reduction of intracellular calcium and are
important in relieving cortical cytotoxicity and motor–cogni-
tive impairments in Parkinsonism. Morphological evidence
(Immunohistochemistry) showed that haloperidol induced
Parkinsonism involves neuronal degeneration, reduced glia
count and depletion of cortical neurofilament. This also
translates into reduced neural activity in the motor cortex and
such animals exhibited impaired motor and cognitive func-
tions in behavioral studies. We have also shown that VDR
potentiation and NMDAR inhibition reduce the cortical
toxicity by improving neuronal metabolism (NSE), glia
count (GFAP) and cytoskeleton to support synaptic function
(NF), thus, an increase in neural activity and motor–cognitive
function.
In this study haloperidol was selected as an inducing agent
as its effect is encompassing. It can selectively target the cells
of the pyramidal and extrapyramidal tract (Deepak et al.,
2008; Espinoza et al., 2011) and inhibit dopaminergic
receptors (D2) (Bertran-Gonzalez et al., 2009; Reavill et al.,
1999). At cellular level, it induces synaptic denervation
through calcium-dependent depolymerization of microtubules
in motor neurons (Cazorla et al., 2014). Furthermore, it
increases glia and cellular activation, creating series of events
similar to inflammation (Bishnoi et al., 2008; Voronkov et al.,
2013). The symptoms of haloperidol induced movement
disorders can result from the ability of the dopaminergic (D2)
antagonist to induce oxidative stress and cause production
of ROS (Byron et al., 2010). The ROS generally increase
the calcium ion concentration by mobilizing calcium
from intracellular and extracellular sources (Drago et al.,
2013; Zhang et al., 2012). Such calcium accumulation
leads to microtubule collapse and excessive phosphorylation
of Tau, a microtubule associated protein involved in
stabilizing the structure of the MT assembly in neurites
(axon and dendrite) (Delotterie et al., 2010; Hasbi et al.,
2009). Several studies have established the effect of
Haloperidol in inducing cytoskeletal disorganization through
ROS generation and hyper phosphorylation of Tau; in certain
experiments 100 mM of Haloperidol, in vitro, caused a
complete cytoskeletal collapse in most cells (Benı´tez-King
et al., 2010a,b).
Previous studies have described the interplay between
calcium toxicity, autophagy and synaptic denervation in
Parkinsonism (Chen et al., 2013; Iba´n˜ez-Sandoval et al.,
2007; Villalba & Smith, 2010). Cellular activation of calcium
through NMDAR and VDR are important in neuronal
development, polarity, migration and synapse formation in
the developing motor cortex. Similarly, these receptors are
implicated in the pathology of degenerative diseases in the
adult nervous system. Elevated cerebral calcium and glutam-
ate coupled with a low serum level of Vitamin D3 is often
Figure 4. Novel objection recognition test for spatial memory and memory index (MI). (a) Comparing the estimated time spent on new objects versus
old objects, the control recorded the highest memory index while the haloperidol treatment had the lowest memory index. In addition, the control spent
more time exploring both objects than all other groups, while the DPD recorded the least exploration time. An improved cognition was observed after
the VDRA intervention in haloperidol treated mice (DPD/+VDRA) when compared with the control and the DPD (p50.01). Similarly, cognitive
function and memory consolidation increased in the haloperidol treatment group that received both interventions (DPD/+VDR/NMDAR) as the
animals explored the novel object and recorded an increase in memory index. (b) Bar chart showing the memory index for the treatment groups and
control. A decline in memory index was seen in DPD and the intervention group without prior haloperidol treatment (NS/+VDR/NMDAR). VDRA
intervention in haloperidol treated mice (DPD/+VDR) caused an increase in the memory index when compared with the haloperidol treatment (DPD)
without intervention (p50.001). Also, the group that received intervention without prior haloperidol treatment showed a decline in memory index
(NS/+VDR/NMDAR). NMDAR inhibition (DPD/NMDAR) and the combined intervention (DPD/+VDR/NMDAR) caused no significant
increase in memory index when compared to the DPD (*p50.05, **p50.01).
DOI: 10.3109/01480545.2014.975355 Vitamin D improves motor fucntion in Parkinsonism 7
D
ru
g 
an
d 
Ch
em
ic
al
 T
ox
ic
ol
og
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
19
7.
21
1.
48
.1
94
 o
n 
11
/0
4/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
associated with Parkinsonism and other degenerative diseases
(Peterson, 2014; Petersen et al., 2013, 2014).
Vitamin D3 (VD) is important in neurodevelopment, up-
regulation of neurotrophic factors, stabilization of mitochon-
drial function and antioxidation (Fuglestad et al., 2013;
Harms et al., 2011; Orme et al., 2013). The VDR gene codes
for the VDR is responsible for calcium regulation, immune
response, neuronal functions (Castellano et al., 1998;
Smolders et al., 2011). Improved motor and cognitive
functions have been observed in amyotrophic lateral sclerosis
(ALS) (Camu et al., 2014), Alzheimer’s disease (Lu’o’ng &
Nguyeˆn, 2011), PD (Peterson et al., 2013) and stroke patients
(Makariou et al., 2014) receiving VDRA placebo supple-
ments. Nissou et al. (2013) demonstrated that the role of VD
goes beyond cellular mechanisms, over time it has been found
to be associated with up regulation of several genes up to 1.9
folds at transcriptome level (Nakahashi et al., 2014; Wo¨bke
et al., 2013). In addition, VDRAs are known to influence
dopaminergic neuron maturation, differentiation and neuronal
melanogenesis through calcium dependent pathways activated
by specific ligand receptors, such as endothelin receptor
(Camu et al., 2014).
Although VDRs are highly localized in the brain, they are
most predominant in the pigmented cell population of
nigrostriatal tract; specifically their projections to the motor
cortex and basal ganglia (Cui et al., 2013; Eyles et al., 2005).
The role of VDR activation in reducing calcium ion
concentration is important for stabilizing neuronal cytoskel-
etal structures, vesicle clearance and synaptic activities, thus,
its activation (VDR+) reduces synaptic denervation and loss
of dendritic spines in the motor pathway (Agholme et al.,
2010; Clelland et al., 2014). Our results show that VDRA
treatment (+VDR) was more effective in improving cortical
structure and function following haloperidol induced cell loss
in the motor cortex. Neuronal and glia cell count increased in
the VDRA intervention group and was significant when
compared to NMDAR inhibition and the combined interven-
tion (Figure 6a and d, b and e). VDRA intervention was also
associated with an increase in NF deposition in the motor
cortex (Figure 6c and f), increased neural activity (Figure 1)
and motor function (Figures 2 and 3). The significant
improvement observed after VDRA intervention can be
attributed to the role of VDRA in mobilization of calcium
for sequestration, thus reducing the intracellular calcium
Figure 5. Elevated plus maze; a test for anxiety. (a) Closed arm duration (CAD) was highest in the DPD thus signifying anxiety in this group, although
the difference in CAD across the treatment and control was statisctically insignificant. (b) OAD was highest in the +VDR/NMDAR when compared
to other groups. In the OFT this group also recorded a high exploratory motor function and reduced anxiety. (c) Composite bar chart comparing the
number of CAE versus OAE. The DPD/+VDR recorded the highest CAE and OAE while DPD recorded the lowest in both. (d) The frequency of head
dipping (HD) was plotted for each group to generate an average. DPD/+VDR/NMDAR showed the highest rate of HD. No significant difference was
recorded in the anxiety-linked behaviors.
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Figure 6. Expression of GFAP, NSE and NF in the motor cortex (immunohistochemistry). (a) Significant loss of glia cells was observed in
the haloperidol treatment group (DPD; p50.001) and the animals that received intervention without prior haloperidol treatment (+VDR/NMDAR;
Continued
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Figure caption Continued
p50.001) when compared with the control. An increase in glia count (GFAP+) was observed in the VDRA intervention (DPD/+VDR), NMDAR
blockade (DPD/NMDAR) and combined intervention (DPD/+VDR/NMDAR) groups. This demonstrates the effect of the intervention in glia
survival and activation for metabolic support and neurotrophic factors production (see also (d)). (b) Depletion of neurons was observed after
haloperidol treatment (DPD); this was seen as a reduced number of NSE immunopositive cells in the motor cortex. This is also suggestive of reduced
neuronal metabolism in stress. Interestingly, animals that received intervention without prior treatment showed a similar NSE(+) count when compared
with the DPD suggesting a possible cytotoxic effect without prior elevated cerebral calcium or toxicity. When compared with the control, neuronal cell
loss in the DPD and +VDR/NMDAR was significant at p50.001. Similar to the outcomes of glia count ((a) and (d)), neuronal count also increased in
the motor cortex of DPD/+VDR when compared with the control (p50.001) and other treatment groups (p50.001). However, NMDAR inhibition
(DPD/NMDAR) and combined intervention (DPD/+VDR/NMDAR) gave no significant change in NSE(+) count when compared with the control
and DPD (e). (c) Loss of neurofilament was observed in the motor cortex of the haloperidol traeted groups (DPD) when compared with the control
(p50.001). Similar to our observations in neuron and glia counts, VDRA intervention also improved neurofilament deposition and cytoskeletal repair
in the cortical cells. An increase in NF was observed in the DPD/+VDR when compared with the haloperidol treatment without intervention (DPD)
(p50.001). DPD/NMDAR and DPD/+CDR/NMDAR showed significant increase in NF expression when compared with the DPD (see also (f))
(magnification 100). [Inset black frame shows higher magnification for cell identification; *represents region of notable cell loss in Figure 6b].
Figure 7. Ki-67 immunohistochemistry. (a) Ki-67 expression in the cortex demonstrates proliferation in the treatment groups following administration
of Vitamin D3 (DPD/+VDR). DPD showed the least count in Ki-67 expression when compared to the control. However, this increased significantly
after the VDRA intervention (p50.001), NMDAR inhibition (p50.001) and combined intervention (p50.001). (b) Statistical analysis of distribution
of Ki-67 immunopositive cells in the motor cortex. The DPD/+VDR group gave the highest score while the DPD had the lowest count (significant at
p50.001). DPD/+VDR/NMDAR treatment also facilitated proliferation but was less significant when compared to DPD/+VDR (p50.01)
(magnification 100). [Inset black frame shows higher magnification for cell identification; *represents region of notable cell loss in Figure 7a].
10 O. M. Ogundele et al. Drug Chem Toxicol, Early Online: 1–13
D
ru
g 
an
d 
Ch
em
ic
al
 T
ox
ic
ol
og
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
19
7.
21
1.
48
.1
94
 o
n 
11
/0
4/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
concentration and the associated excitotoxicity. Furthermore,
the VDRA is a steroid (calcitriol) capable of crossing the
nuclear membrane to promote gene expression and transcrip-
tion of proteins for cellular repair and metabolic shifts
required for cell survival. To demonstrate cell viability
following VDRA intervention, Ki-67 was quantified using
stereologicaly. We observed a significant increase in Ki-67(+)
cells in the motor cortex after VDRA intervention in the
haloperidol treatment group (Figure 7a and b) (p50.001).
Comparing this with the counts form NSE and GFAP, we
observed that glia proliferation was more than neuronal
proliferation in the motor cortex. The Ki-67 score in the DPD
cortex was significantly low and was further confirmed
by comparing the Ki-67 with the GFAP and NSE count for
this group.
The use of +VDR and NMDAR in therapeutic targeting
for PD proved useful in this study similar to the proposition of
Liu et al. (2013). The effect of +VDR was more significant
when compared with NMDAR inhibition while +VDR/
NMDAR post DPD also improved cognitive and motor
function in the experimental model. Motor function increased
in the DPD/+VDR treatment with an increased latency of fall
and reduced passive rotations in the Rotarod test. This was
also supported by the improved neural activity in the motor
cortex in vivo, with maximum peaks similar to the control
(Figure 1). The +VDR/NMDAR group that received
intervention without prior haloperidol treatment also showed
a decline in forced motor activity on rotarod and an increased
number of passive rotations (Figure 3b). This was further
supported by the reduced neural activity recorded for this
group (Figure 1c) – slightly higher than those recorded for the
DPD (Figure 1b and g). Similarly, memory function was
highest in the VDRA intervention group (Figure 4a and b)
when compared with the control and the NMDAR inhibition
group (DPD/NMDAR). Comparing the memory index, the
DPD explored the old object more than the new object, thus a
decline in memory index when compared to the control. After
VDRA treatment in the DPD/+VDR, the memory index
increased as the animals explored the new object more and
recorded an increase in exploration time of both objects. The
DPD/NMDAR gave only a minor improvement in memory
index when compared with the DPD/+VDR for the same
intervention period. The reduction in neural depolarization
potential observed in haloperidol treatment shows the effect
of synaptic denervation in prolonged exposure to drugs,
radicals or calcium surge at the synaptic endings (Liu et al.,
2010). Although VDRA intervention improves cortical func-
tion, the actual mechanism of VDR–VDRA linked cytoskel-
etal restoration in Parkinsonism is an area to be explored in
drug development.
Conclusion
VDR activation and NMDAR inhibition improved motor
functions following haloperidol induced degeneration and cell
loss in the motor cortex. The VDRA treatment was more
effective as demonstrated in the behavioral studies and in vivo
neural activity recordings in the motor cortex. This was
further supported by demonstration of neuron survival marker
(NSE) and the presence of glia cells (GFAP) in the cortex to
produce growth factors to aid survival of neurons after VDRA
intervention. Ki-67 staining further supports the findings that
+VDR increases the rate of neuron and glia survival and
proliferation in the motor cortex. We conclude that improved
motor function following VDRA intervention is associated
with an improved neural activity and cytoskeletal deposition
modulated by VDR–VDRA through the reduction of intra-
cellular calcium. In addition, VDRA activation also facilitated
increased protein synthesis for metabolic support (NSE) and
synaptic repair (NF).
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